Country: Canada
Language: English
Source: Health Canada
IMATINIB (IMATINIB MESYLATE)
MINT PHARMACEUTICALS INC
L01EA01
IMATINIB
400MG
TABLET
IMATINIB (IMATINIB MESYLATE) 400MG
ORAL
15G/50G
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0145503003; AHFS:
APPROVED
2019-09-18
_MINT-IMATINIB(Imatinib Mesylate Tablets) _ _Page 1 of 74_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr MINT-IMATINIB Imatinib Mesylate Tablets Tablets, 100 mg and 400 mg imatinib (as imatinib mesylate), Oral Protein Kinase Inhibitor ATC Code: L01EA01 Mint Pharmaceuticals Inc. 6575 Davand Drive Mississauga, Ontario L5T 2M3 Date of Initial Authorization: SEP 18, 2019 Date of Revision: NOV 14, 2023 Submission Control Number: 277157 _MINT-IMATINIB(Imatinib Mesylate Tablets) _ _Page 2 of 74_ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, Musculoskeletal 11/2022 1 Indications 11/2023 4 Dosage and Administration 11/2023 7 Warnings and Precautions, General 11/2023 7 Warnings and Precautions, Hepatic/Biliary/Pancreatic 11/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ......................................................................................................... 2 TABLE OF CONTENTS ........................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................................. 4 1 INDICATIONS .......................................................................................................................... 4 1.1 Pediatrics ..............................................................................................................................4 1.2 Geriatrics ..............................................................................................................................4 2 CONTRAINDICATIONS ............................................................................................................. 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................................ 5 4 DOSAGE AND ADMINISTRATION ................................................................................ Read the complete document